1185 AVENUE OF THE AMERICAS, 3RD FLOOR, NEW YORK, NY
Annual Report to Security Holders
Oramed Pharmaceuticals Inc. Approves Fifth Amended and Restated Bylaws
Material disclosure
Oramed Pharmaceuticals Enters Warrant Agreement with Scilex Holding
Announce Strategic Transaction
Receives $18 Million Payment from Holdings, Bringing Current Returns to $118 Million; Board Approves Dividend Payments
Director Resignation - Leonard Sank Steps Down from Oramed Board
Other Events
Q2
Q1
Notice of Late Filing for Quarterly Report
FY 2025
Q3
Amended Annual Report
Registration of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Amended Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Quarterly Report Transition
Prospectus filed pursuant to Rule 424(b)(7)
Correspondence